KRAS and acute myeloid leukemia: Another two studies—the first featuring 232 AML patients with de novo AML, AML with myelodysplasia-related changes, or therapy-related AML at the time of induction chemotherapy who had next-generation sequencing performed prior to treatment, and the second featuring 239 newly diagnosed AML patients with various AML subtypes for whom RAS mutational status was determined using a next-generation sequencing myeloid panel—revealed that KRAS mutations were correlated with worse outcomes, while NRAS mutations had no impact on outcomes [8,23].